Nektar Therapeutics | NKTR - Interest Expense On Debt


Nektar Therapeutics reported $7.94M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.06B 44.38M Sep/2026
ALKERMES USD 27.55M 1.63M Sep/2026
Amgen USD 653M 94.99B Sep/2026
Baxter International USD 64M 14M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 403M 4M Sep/2026
Cara Therapeutics -89.64M 128.67M Dec/2025
Cipla INR 167.4M 2.9M Sep/2026
Dr.Reddys Laboratories INR 1.26B 198M Jun/2026
Eisai JPY 1.96B 409M Jun/2026
Eli Lilly USD 316M 201.3M Sep/2026
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Incyte USD 605K 23K Sep/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
MacroGenics USD 4.4M 493K Jun/2026
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Pfizer USD 662M 5M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
Takeda JPY 63.38B 466M Sep/2026
Teva Pharmaceutical Industries USD 414M 219M Sep/2026
Xencor USD 4.11M 3.24M Sep/2026